Biocom LifeLines - Summer 2014

LifeLines For the Southern California Life Science Community

7

Proud of Our Leaders and Leadership

20

Providing Tangible Value Through Sponsorships

24

Veterans in Life Science

Innovation’s Perfect Climate: The Big Pharma Perspective

Volume 23, Issue 2 S u m m e r 2 0 1 4

ONE TEAM, ONE FOCUS

www.sdlifesciences.com

TENANT REP FOR THE LIFE SCIENCES INDUSTRY

AltheaDx

Verenium / BASF

Cubist

Genomatica

70,000 SF Tenant Representation

Biocom

60,000 SF Tenant Representation

10,900 SF Tenant Representation

Lilly

45,000 SF Sublease Disposition

70,000 SF Tenant Representation

125,000 SF Tenant Representation

Pfizer

Genzyme / Sanofi

Biogen Idec & Illumina

45,000 SF Sublease Disposition

(858) 452-6500

64,000 SF Sale Disposition

BRENT JACOBS

GREG BISCONTI

TED JACOBS

CA LICENSE NO. 791657

CA LICENSE NO. 1167920

CA LICENSE NO. 1855220

350,000 SF Sale/Lease Disposition

WELCOME

I n T h is I ss u e 2

Cover Story: Innovation’s Perfect Climate: The Big Pharma Perspective

7

Public Policy :Proud of Our Leaders and Leadership

8

San Diego Selected to Join Global Cities Initiative’s New Metro Foreign Direct Investment Pilot

9

Exhibit your new medical technology at Biocom’s Med Device Expo

Members in Action: Legislative Roundtable Scott 11-14 Peters, Legislative Roundtable Juan Vargas, Global Life Science Partnering Conference, Biocom PAC Legislative Staff Reception, Biocom Golf Tournament

16 Guest: Zykadia is San Diego Research Group’s First FDA Win for Novartis

18 BiocomConcierge.org – Time Saving Business

Solutions ur new medical technology at Biocom’s Med Device Expo

20 Events: Providing Tangible Value Through Sponsorships

23 Festival Week a Big Success 24 Veterans in Life Sciences 26 Biocom Purchasing Group: Power in Numbers 28 Premium Member Spotlights: Ajinomoto Althea, Conatus Pharmaceuticals, Mintz Levin, Praxair, VWR

31 Biocom Board and Committees 32 Biocom Membership E d i to r : Jennifer Landress CO P Y E d i to r : Josh Baxt DESIGN & LAyout: Arlene Arreola V o l u m e 2 3 , I ss u e 2

Biocom, a member driven organization is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development.

By Joe Panetta, President and CEO, Biocom

GOOD News Welcome to the summer 2014 edition of Lifelines and a sincere welcome to everyone attending the BIO 2014 International Convention. We at Biocom are proud to be co-hosting the meeting with the Biotechnology Industry Organization and our California life science association partners. This marks the third time since 2001 that BIO has come to San Diego, where the regional biotechnology industry and the convention itself have reached new heights. I hope that your experience at BIO is exceptional, whether you are attending as a member of Biocom or visiting from afar.

This year, we are particularly excited to highlight San Diego’s growth in personalized genetic medicine and digital health, which were just beginning to develop when BIO visited San Diego in 2008. Biocom has grown as well, with a new Washington, D.C., policy office, an annual Global Partnering Conference and a nationally-recognized institute for education and workforce development. This fall, we will move into our first new offices in more than 15 years. Located on Torrey Pines Mesa, where the San Diego biotech industry was born more than 35 years ago, the new facility will better serve the Biocom community.

In our cover story, Cammy Duong of Canale Communications paints an in-depth portrait of life science innovation in San Diego. The article focuses on why “big pharma” has expanded its presence here from the perspectives of six executives who represent a few of the major companies. There is a common theme in the interviews – praise for the unique collaborative climate and entrepreneurial spirit in our universities, research institutes and life science companies. In addition, the executives agree that the talent base in San Diego is unsurpassed by any other region, bringing an exceptionally innovative approach to the research.

San Diego is also known for hosting the U.S. Navy’s largest West Coast port, as well as a Marine Corps air station, recruit depot and Camp Pendleton. This presence contributes exceptional veterans, who offer much to our workforce. As new Biocom Institute executive director Liisa Bozinovic describes in her article, the Institute plays a major role in training these veterans for careers in the life science industry. The Institute also works closely with the San Diego Festival of Science and Engineering, a successful event that is recapped by its director Sara Pagano.

On the membership and events side, we show how companies receive tangible value from sponsorships, offering perspectives from two of our sponsors. We also describe our newly-launched concierge web site and provide a case study from our Purchasing Group on the competitive RFP process that Biocom uses to select vendors.

The future of life science is happening here in San Diego, and Biocom is positioned to accelerate that growth. Please enjoy your time in San Diego at BIO 2014 and return soon to participate in our vibrant life science industry.

www.Biocom.org

Biocom LifeLines Summer 2014

1

Cover Story

By Cammy Duong, Canale Communications

Innovation’s Perfect Climate: The Big Pharma Perspective exhibited a strong bent towards social Darwinism – only the fittest The first time the BIO International Convention came to San will survive – San Diego proves to be the exception to this barbaric Diego in 2001, expectations for the region were uncertain, as paradigm by offering a more collaborative spirit. This approach, San Diego was considered a distant third among biotech clusters. along with a hefty stock of brainpower, talent and cross-sector However, that year, BIO San Diego broke attendance records and resources, is one of the many reasons big many still today say it was one of the best pharma thinks the region offers a perfect conventions ever.

“The main rationale for climate for success and innovation.

With a “little engine that could” mentality, being in San Diego is the We asked executives from six big pharma the region has now been recognized as a life entrepreneurial and scientific companies in our region for their perspectives science powerhouse. Some reports, such on innovation in San Diego and why their as a 2013 report from Jones Lang LaSalle, activity in the life sciences. rank San Diego the second largest cluster Our presence here is extremely companies find it strategically beneficial to have a footprint in the region. in the world. The region has the resources to support hundreds of companies in strategic bec ause it allows us to be in close connection with Why San Diego? existing and emerging sectors, home-grown Mackay: AstraZeneca acquired San Diegotechnologies that provide the foundation for the community of scientists based Ardea Biosciences in order to develop life-altering diagnostics and therapeutics, and entrepreneurs that give a gout franchise lead by Ardea’s lead phase and a differentiated innovation climate that us access to a diverse and 3 molecule, lesinurad, while also gaining has attracted large pharmaceutical and access to Ardea’s gout knowledge and the biotechnology companies from around the differentiated type of talent.” company’s biotech approach to development. globe to set up shop in America’s Finest --Diego Miralles, Janssen Our goal is to maintain Ardea as an City.

R&D unit in San Diego and progress the While the life science industry has always

2

Biocom LifeLines Summer 2014

Cover Story

James Mackay, Global Product Vice President, Lesinurad and Ardea Biosciences, AstraZeneca

Damien McDevitt, PhD, VP Business Development and Site head West Coast, GlaxoSmithKline

Diego Miralles, MD, Global Head of Innovation, Janssen Pharmaceuticals

James Schaeffer, PhD, Executive Director, Worldwide Licensing and External Research – West Coast, Merck Research Laboratories

Bhasker Shetty, PhD, Vice President, Pfizer Worldwide R&D and La Jolla Laboratories

David Weitz, JD, Senior Vice President, General Counsel and Chief Intellectual Property Counsel, Takeda California

development of lesinurad, and the broader gout franchise, by utilizing the knowledge and expertise at Ardea while retaining their biotech culture.

McDevitt: GSK has been working with academia, venture capital firms and biotechnology companies on the West Coast for years, but we realized that having an office on the West Coast would help us work more closely with our existing partners and also identify and develop new relationships. Last October, we announced plans to open an R&D satellite office in San Diego and hope to move into our new space in Torrey Pines later this year.

Externalization is a core part of GSK’s R&D strategy because we believe that the next generation of medicines will come from true collaboration among pharma, academia, venture and biotechs.

We chose San Diego as the location for our first West Coast office primarily because of our relationship with Avalon Ventures, but our reach extends all the way up the West Coast – stretching from San Francisco to Seattle.

Miralles: Johnson & Johnson has had a large presence in San Diego from our sales force for our three businesses – consumer, pharmaceuticals and devices. In the 1990s, we established a relationship with The Scripps Research Institute, on Torrey Pines Mesa. Through that collaboration, we hired Scripps researcher Per Peterson, who had the vision to build a drug discovery unit here in San Diego. The site took five years to complete and is now home to Janssen R&D. Schaeffer: This is where scientific innovation resides. There are innovative scientists at all major universities and biotech hubs; however, they do not encompass all the exciting new companies.

There is a strong rationale for being embedded within this type of vibrant scientific community.

Shetty: After we became Pfizer in 2000, the company decided to locate all their R&D sites to big innovation hubs. Our site in San Diego was the first Pfizer R&D site to be located in an innovation hub and continues to be a dynamic “There is a great spirit of and productive openness, collaboration and site.

Weitz: Takeda c amaraderie in San Diego.” entered San --David Weitz, Takeda Diego in 2005 by acquiring a company that, at the time, had 85 employees and a focus on small molecule structure-based drug discovery with compounds in clinical development. With an investment of over $1 billion, Takeda has grown its presence in San Diego to more than 200 employees, with research in four therapeutic areas supported by multiple in-licensed drug discovery-enabling technology platforms.

Biocom LifeLines Summer 2014

3

Cover Story the opportunity to build on that foundation and thus utilize the How has your company benefitted from having a presence in San best of biotech and the best of large pharma.” --James Mackay, Diego?

AstraZeneca Mackay: San Diego is a center for highly innovative R&D and McDevitt: One of the key drivers behind GSK establishing a thus attracts a very high caliber of scientists and drug development San Diego-based R&D satellite office is to enhance our strategic professionals. Additionally, the biotech network in San Diego discovery collaboration with Avalon Ventures as we build up to 10 allows AstraZeneca to tap into the broad range of innovation that is biotech companies together. Our greatest happening in the region through the Ardea opportunity lies with our ability to create the experts and their personal networks.

“I really believe that the right partnerships that will advance the best McDevitt: GSK and our partners will biggest/best opportunities science and lead to new and differentiated benefit from our presence in San Diego are yet to be achieved.

I am medicines for patients. because our team will be in tune with what Miralles: There are many opportunities GSK’s R&D wants to do, and we’ll know the not prescient enough to know in San Diego, such as connecting with the right person in R&D to bring the ideas to. what they are, but I am curious local life science community, living with It’s about making connections, knowing enough to want to be here when scientists and entrepreneurs and having which opportunities to seek out and being a such a close proximity to the biotech life bridge to GSK’s global R&D function. they occur.” sciences ecosystems.

Miralles: Our presence allows us to --James Schaeffer, Merck Schaeffer: On a personal level, it’s the be a California company, which gives us access to many smart and innovative access to leadership talent that would be entrepreneurs. This is an extremely collegial community, and the unattainable if we were based solely in New Jersey. This location free exchange between academics, biotechs and big pharma is allows us to think differently and build on our perspective to what exciting. otherwise would be a very centralized company with a one-sided Shetty: The San Diego ecosystem has a strong track record, view of the world. spanning several decades, in spawning companies that deliver Schaeffer: Our San Diego presence has helped raise Merck’s breakthrough biopharmaceutical technologies and products to the profile within the region’s scientific community. It is not a market. coincidence that we have numerous collaborations with San Diego Weitz: People want to live and work in San Diego. That creates and San Francisco. opportunities in terms of recruiting, retention, and opportunities to Shetty: Our location has helped us interact and build collaborations collaborate locally. with the best scientists and institutes in San Diego. We also have access to numerous start-ups and biotechs that are interested in What is unique about San Diego‘s life science ecosystem? What is collaborating. the biggest opportunity for San Diego as a Weitz: Takeda California provides its life science cluster? parent company with a valuable San Diego “These companies are often Mackay: Not many people outside the and California research hub, into which it region are really aware of the tremendous can absorb talent, technology and product acquired for large sums. innovation that exists in San Diego. It has opportunities.

Success breeds success; been in existence for such a long period of we benefit greatly from the time that the intrinsic network in the region What do you see as the single biggest experienced talent pool of the functions seamlessly and also benefits from opportunity for your company in San Diego? the significant armed forces investment and Mackay: Maintaining a functioning biotech San Diego ecosystem, and from innovation that is focused in the region. San unit in San Diego allows AstraZeneca access the opportunity to partner Diego is a hidden gem in the global biotech to the innovative biotech company thinking loc ally for innovative science world and has access to such a thriving and scientific innovation in the San Diego network of innovation. The opportunity is to region. This is important because it allows and products.” make that visible to the world. San Diego us to push the boundaries of science in --Bhasker Shetty, Pfizer has a track record of creating a culture order to deliver life-changing medicines. that allows innovative science to drive “The combination of a nimble, focused transformation of our understanding of and highly efficient biotech with the diseases and thus the development of life-changing medicines. global reach and power of a large pharma has proved to be a very McDevitt: San Diego is one of the densest biomedical research successful model for Ardea and AstraZeneca. San Diego provides

4

Biocom LifeLines Summer 2014

high tech as a big opportunity for San Diego to improve healthcare communities in the world, including world-leading academic through big data, digital health and patient-centered services. This centers, such as UCSD, The Scripps Research Institute, Sanfordallows us to harness the unique collaborative environment of San Burnham and Salk. The availability of scientific and medical talent Diego to focus on the integration of life science and high tech to to support the biotech ecosystem is also unique. give us a competitive edge.

Miralles: The region is unique because it is an incredibly tightWeitz: San Diego is a community that supports one another and knit community. We are truly supportive of each other’s victories and roots for the success of the community as a whole. Life science encourage each other to succeed. The single biggest opportunity talent will continue to concentrate in for San Diego is in the genomics space. clusters, and each new San Diego success With tremendous academic and research “There is a strong culture of a story fuels the cluster’s further success. institutes and genomic visionaries, this life science community where creates a unique ecosystem that provides San Diego’s diligent and rapid growth as a the opportunity for San Diego to become the everyone tends to be helpful life science cluster can be greatly attributed center of the applied genomics revolution. and supportive, encouraging to the diverse makeup of companies—big Schaeffer: The two most obvious collaboration rather than and small—and ideas that have made it opportunities are the future growth of human a resilient force through tough economic genomics as a tool for faster/more effective competition. This collegial times. With a strong foundation of large target identification and drug discovery and approach is key if we are pharma anchor companies, biotechs, the advancement of ‘electronic medicine.’ to deliver innovative new digital health startups, venture capitalists Both of these areas are growing rapidly medicines to patients. and academic and research institutions in San Diego because of the presence working collaboratively together, there’s no of such powerhouses as Qualcomm, Life --Damien McDevitt, question San Diego has found the secret Technologies/Thermo Fisher, Illumina and GlaxoSmithKline to success. Having evolved into a place Calit2. where life science and technology are Shetty: San Diego is unique for being converging, San Diego is poised to become the leading life science collaborative and not competitive. Many of our institutes work in cluster in the world within the next 10 years. collaboration and many larger initiatives are tackled as a result these productive interactions. We see the convergence of life science and

Biocom LifeLines Summer 2014

5

69,808 square feet

10,335 square feet

We are pleased to announce that AltheaDx and Arcturus Therapeutics have each chosen to relocate their corporate headquarters to the Torrey Ridge Science Center in the coming months!

Additional class A laboratory space

AVAILABLE 10,000 to 250,000 square feet

For more information, please contact:

Rich Danesi Lic. 01869864 +1 858 546 4652

richard.danesi@cbre.com

Ryan Egli Lic. 01445615 +1 858 546 4648 ryan.egli@cbre.com

Public Policy

By Jimmy Jackson, Vice President of Public Policy, Biocom

Proud of Our Leaders and Leadership In the public policy realm, the beginning of the year has been quite active. On May 12, Assemblywoman Toni Atkins of San Diego was elevated to the office of Speaker of the Assembly. On a policy level, this position is one of the three most powerful in the state, the other two being the governor and the President Pro Tempore of the State Senate. Speaker Atkins, the first San Diegan in history to hold this office, is a longtime friend of Biocom and our members and represents much of San Diego’s life science cluster.

Federally, the specter of another patent reform battle has gone from a matter of concern to a very real and present threat.

Biocom’s full-time Washington D.C. lobbyist, Laure Fabrega, is working closely with BIO and other strategic partners to ensure that the ability to defend intellectual property protection is preserved.

In other important news, Biocom continues to work to raise the NIH appropriation to $32 billion, a figure agreed upon by stakeholders, including patient groups and a bipartisan Congressional group led by Congresswoman Susan Davis (D-San Diego). Biocom is participating in a number of efforts, both in partnership with other organizations and member companies and during individual lobbying meetings, to make this goal a reality this year.

On May 20, Biocom was one of a coalition of fifteen regional associations to convene a very successful Capitol Hill briefing, entitled Public-Private Partnerships: Advancing Treatments and Cures. This was followed by a well-attended reception for members of Congress, their staffs, and Biocom member companies with a presence in Washington D.C. Since the beginning of the year, Biocom has also hosted a number of conversations with our elected leaders. We sponsored a general roundtable, as well as one specific to the wireless health industry, with Congressman Scott Peters. We held another general roundtable with Congressmen Peters and Steny Hoyer, the second ranking Democrat in the House of Representatives. In addition, we had a member call-in discussion with Congressman Duncan Hunter and a roundtable on life science financing solutions with Congressman Juan Vargas.

In Sacramento news, this year the industry faced legislation that would make the life science industry create or contract for takeback programs for both pharmaceuticals (SB 1014) and sharps (AB 1893). Both bills would have made the life science industry, and only the industry, responsible for the costs and administration of these programs, despite the acknowledgement that effective take-back programs require participation and some level of

responsibility by ALL stakeholders, including patients/consumers.

Thanks to an aggressive education campaign by a coalition of industry associations (Biocom, AdvaMed, BayBio, BIO and CHI) and a number of individual companies, it became clear neither bill had the legislative support to move forward. These bills have been substantially amended and while they no longer generate the draconian potential costs they once did, they remain prominent on Biocom’s radar.

Locally, Biocom continues to solidify our relationship with new San Diego Mayor Kevin Faulconer, who Biocom endorsed in the February special election. Joe Panetta, President and CEO of Biocom, was named to Mayor Faulconer’s transition committee, which will help him identify and set his administration’s priorities in the coming year.

In a major victory for the business community, on March 4, the San Diego City Council repealed its 400 percent increase in linkage fees paid during new construction or renovation and used towards affordable housing. Biocom was a founding member of the coalition opposing this increase and continues to monitor the discussions towards a long-term solution.

Finally, please welcome Melanie Nally, Associate Director of Local Government and Regulatory Affairs, to the Biocom public policy team. Melanie joined us in February of this year and has already been an effective voice for Biocom at the San Diego City Council and regulatory agency meetings.

If you would like to keep up with these and other pressing issues as they happen, please see the Public Policy section of the Biocommunique electronic newsletter.

Jimmy Jackson is the Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

Biocom LifeLines Summer 2014

7

INITIATIVE

San Diego Selected to Join Global Cities Initiative’s New Metro Foreign Direct Investment Pilot In April of this year, San Diego announced that it joined a pilot to create and implement plans to attract foreign direct investment as part of the Global Cities Initiative, a joint project of the Brookings Institution and JPMorgan Chase. This metro foreign direct investment pilot is the next phase of the Initiative’s Exchange, a network of metropolitan areas committed to establishing actionable plans that will promote greater global trade and economic competitiveness.

San Diego joined the cities of Columbus, Ohio; MinneapolisSaint Paul; Portland, Ore.; San Antonio; and Seattle, WA. Each region is tasked with creating a process for developing their foreign direct investment plan and preparing a report that will be published later this year. Brookings selected these six metro areas after an extensive application process. San Diego was selected for its readiness and commitment to strategically pursue foreign direct investment such as greenfield expansions, mergers and acquisitions, and other types of foreign investment including equity joint ventures, and sovereign wealth funds.

Foreign direct investment has long supported regional economies, not only by infusing capital, but also by investing in workers, strengthening global connections and sharing best business practices. As the world’s largest economy with a stable investment environment, the United States has been a top destination for foreign direct investment. Yet in the world’s increasingly competitive investment market America’s global share of foreign direct investment has fallen.

For America to regain its standing, cities and metropolitan regions must capitalize on their comparative advantages to secure more of this growing, global source of investment. Metropolitan leaders, in partnership with their states, are best equipped to promote their areas’ unique appeal, establish strategic and mutually beneficial relationships, and attract foreign direct investment. San Diego is well positioned to make foreign direct investment a central component of broader regional economic development strategies.

San Diego will be represented in the pilot by a team of local leaders including Mark Cafferty of San Diego Regional EDC, Joe Panetta of Biocom, Councilmember Mark Kersey of the City of San Diego, Dean Peter Cowhey of the University of California San Diego’s School of International Relations and Pacific Studies and Monique Rodriguez from Qualcomm.

Under the leadership of City of San Diego Mayor Kevin Faulconer, the Metro Foreign Investment program will help pioneer

8

Biocom LifeLines Summer 2014

the region’s global competitiveness strategy.

San Diego’s existing stronghold on the life sciences industry will help focus the FDI strategy. With more than 600 life sciences companies and more than 80 research institutes, biotech is a driving example of how a successful foreign direct investment strategy can promote the region’s competitiveness.

“The region’s global mindset is apparent when you look at thriving life sciences industry,” said Joe Panetta, president and CEO of Biocom. “International companies have long looked to San Diego for its world-class talent pool and abundant research opportunities. San Diego’s new collaboration with Brookings not only means that the region has an opportunity to create more jobs, but also that we will be looked at as a role model for other areas looking to embrace the global economy.”

Qualcomm Incorporated—San Diego County’s largest private employer— will also be a key collaborator on the strategy. The mobile giant’s presence currently adds $4.53 billion to the regional economy annually.

As part of the pilot, San Diego will develop a foreign direct investment market assessment and plan, along with an implementation plan. This work, added to the region’s existing export plan, forms the second core component of a global engagement strategy that will strengthen the region’s global economic connections and competitiveness.

Launched in 2012, the Global Cities Initiative is a five-year joint project of Brookings and JPMorgan Chase aimed at helping city and metropolitan leaders become more globally fluent by providing an in-depth and data-driven look at their regional standing on crucial global economic measures, highlighting best policy and practice innovations from around the world, and creating an international network of leaders who ultimately trade and grow together.

INITIATIVE

Exhibit Your New Medical Technology at Biocom’s Med Device Expo Biocom’s 8th Annual Medical Device Expo will be at the Sheraton hotel in Carlsbad on August 28th 4:30-6:30pm. Sign up to exhibit by June 30th and save $200 plus receive a complimentary admission to DeviceFest, Biocom’s full day medical device conference (earlier in the day) and receive two additional Expo admissions ($40 value for members and $100 for non-members).

If your company has an innovative technology or product that is either currently under development, has been updated or has initially gone to market within the last two years, this expo is for you.

Top 5 reasons to exhibit: 1. Meet with Investors, VC’s and Hospital Administrators 2. Increase visibility for your technology & company 3. Network with 200+ members of the community 4. Have an opportunity to win one of five prestigious awards 5. Receive a complimentary admission to DeviceFest if you register by June 30th ($130 value for members and $170 for non-members) 2013 Past Judges: 12+ VC’s, Investors, and hospital administrators will meet with exhibitors to learn more about their technology, while deciding which companies will receive an award for technical excellence and medical significance.

Opportunity to win one of five awards: “Why didn’t I think of that?”

“I would invest in this” “Far Out!” “Life Changing” “People’s Choice” – audience decides

2014

Sign up by June 30th to save $200 plus receive a complimentary admission to DeviceFest. To request an exhibitor application or learn more, please contact Michelle Wright at mwright@biocom. org or 858.455.0300 x116. You may also visit www.biocom.org for more details and/or to register as an attendee to view new technology from over 20 companies.

August 28, 2014 Sheraton Carlsbad Resort & Spa 9 www.biocom.org

Biocom LifeLines Summer 2014

“Our unwavering commitment to serving patients is at the heart of everything we do at Ignyta.

Working with BioMed Realty to expand our San Diego laboratory and office space by 500% allowed us to focus on our mission of bringing new cancer therapies to patients. We are grateful for BioMed Realty’s assistance in meeting our facility needs.”

— Jonathan Lim, M.D., Chairman, CEO and Co-Founder, Igynta, Inc.

helping our partners manage their growth

For more information contact Tracy Murphy at 858 207 5931

10

Biocom LifeLines Summer 2014

biomedrealty.com

@biomedrealty

MEMBERS IN ACTION

Legislative roundtable: Scott Peters LEGISLATIVE ROUNDTABLE WITH congressman SCOTT PETERS: Biocom’s legislative roundtable discussions give members the unique opportunity to discuss issues important to them directly with their elected representatives in an intimate setting.

On March 19th, Biocom hosted a Roundtable Discussion with Congressman Scott Peters to discuss mHealth (a term used for the practice of medicine and public health supported by mobile devices). Topics included FDA oversight of mHealth, moving the concept of population health beyond medical practice to enable the individual to proactively maintain his/her health using mobile devices, and expanding the scope of Meaningful Use Stage 3 to ensure synergy between real time data collection and electronic health records. During the discussion, Congressman Peters espoused his desire for increased NIH funding and building support for innovation within Congress.

Congressman Scott Peters, Magda Marquet of Ajinomoto Althea, Inc. and Joe Panetta of Biocom.

Mechanisms of Connection Our knowledge, skills and strategic understanding of the Life Science landscape assure your message will connect to your audiences.

Assessing your core values through a comprehensive, creative and consensus-driven collaborative process enables us to establish stronger bonds of connection.

We call this mechanism PUTTING A FACE ON THE FACTS. Corporate Branding • Website Design & Development Collateral • Corporate Decks • Animation

ALDEN MARKETING COMMUNICATIONS 2171 India Street Suite C San Diego CA 92101 aldenmc.com contact@aldenmc.com 619 544 9299

MEMBERS IN ACTION

Legislative roundtable: Juan Vargas

GLOBAL LIFE SCIENCE PARNTERING CONFERENCE

Photos : JT MacMillan Photography

LEGISLATIVE ROUNDTABLE WITH Congressman JUAN VARGAS: Congressman Juan Vargas joined Biocom members on April 23rd for an Roundtable Discussion on an idea he is exploring for alternative funding models for life science companies. As traditional funding through private and public equity becomes more challenging, a funding gap - frequently referred to as “valley of death” - occurs between basic research and clinical development. Congressman Vargas asked Biocom to convene this group to discuss the issues and viability of financing a large number of biomedical projects with securitized debt, creating “megafunds,” which would open up a larger pool of capital for investment. The theory behind the technique is that it would reduce investment risk by greatly diversifying portfolios. Congressman Vargas plans to continue to explore legislation and will continue to work with Biocom, CONNECT, and other interested parties GLOBAL LIFE SCIENCE PARTNERING CONFERENCE. The 4th Annual Partnering Conference is an exclusive forum that brings together BD professionals from leading

pharmaceutical and biotech companies. Clockwise from left: Howard Asher of Abnology, Mason Matthies of RR Donelley; Panel discussion Emerging Trends in Business Development Partnerships; Conference Chairs: Mark Wiggins of Elcelyx, Jennifer Cayer Formerly of Rempex Pharmaceuticals, Jim Schaeffer of Merck Research Laboratories and Igor Bilinsky of Vical; Matt Ritter and Peter Haberz of TSRI

12

Biocom LifeLines Summer 2014

MEMBERS IN ACTION

Biocom PAC LEGiSLAtiVE StAFF ReCEPtion: On March 12th, The Biocom Political Action Committee

(Biocom PAC) held its annual Legislative Staffers’ Appreciation Reception, sponsored by SDG&E. At the event, Biocom members had the opportunity to meet legislative staff representing 17 different elected offices at all levels of government to educate them about the industry, and develop relationships which can prove useful in the future. This event is unique to Biocom in that it focuses specifically on the legislative staffers who make their offices run and who often are responsible for briefing elected officials on issues of importance. Biocom members are able to thank these staffers for their hard work and get to know them in a relaxed, collegial environment.

Clockwise from left: Almis Udrys from the Office of the Mayor Kevin Faulconer, Larry Stambaugh, Chair, Biocom Public Policy Committee, Michael Hadlund from the Office of Assemblymember Rocky Chavez and Deanna Spehn from the Office of the Speaker of the Assembly Toni Atkins; Riley Webb from the Office of Councilmember Scott Sherman, Sandra Dedic of SDG&E, Rob Knudesend from the Office of Assemblmember Brian Maienscheim and Almis Udrys from the Office of the Mayor Kevin Faulconer Joe Panetta of Biocom addressing the attendees

Biocom PAC Legislative Staff Reception

MEMBERS IN ACTION

Biocom charity golf tournament. Clockwise from left:

Joe Panetta of Biocom, Fritz Bittenbender of BIO, Steven Mento of Conatus Pharmaceuticals, and Larry Stambaugh of Apercu Consulting; David Enloe of Althea Technologies, Noel Massie of UPS, David Webb of Scripps Research Institute and Jeff Walsingham of UPS; COI members in VWR tent: Sandy Madigan, Jenny Arthur, Michael Garcia and Jay Litcher from COI Pharmaceuticals.

Golf tournament

Legal Counsel to the Life Sciences Industry • Formation and Organization • Intellectual Property • Clinical Trials • FDA Regulatory • Healthcare Regulatory • Labor and Employment • Real Estate • Litigation

Contact:

Kirt Shuldberg, Partner and Co-chair Life Sciences Practice kshuldberg@sheppardmullin.com | 858.720.7442

Beijing | Brussels | Century City | Chicago | Del Mar | London | Los Angeles | New York Orange County | Palo Alto | San Diego | San Francisco | Seoul | Shanghai | Washington, D.C. www.sheppardmullin.com

Your Virtual Data Room

Strategic Partnerships

From Star tup

IP Licensing Deals

Fundraising

to

Exit M&A

A n d a l l t h e f u n s t u f f i n between

ď ?Only $200 a month

Do Diligence.

Contact us now for a FREE TRIAL BIO INTERNATIONAL ATTENDEES: LEARN more at booth #6144 in the BIO IT Zone.

sales@securedocs.com 866.700.7975 securedocs.com

Guest

By Mandy Jackson, West Coast Editor, SCRIP Intelligence

Zykadia is San Diego Research Group’s First FDA Win for Novartis The Genomics Institute of the Novartis Research Foundation (GNF) in La Jolla recently reached a major milestone: the first U.S. Food and Drug Administration (FDA) approval for a drug discovered

by GNF – the cancer therapy Zykadia (ceritinib).

Fifteen years after GNF’s founding, the FDA approved Zykadia to treat anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) in patients whose cancer has progressed after treatment with Xalkori or who cannot tolerate the Pfizer drug.

It’s the first medicine approved for that indication. In addition, the FDA decision came four months earlier than expected due to the drug’s breakthrough therapy designation.

The FDA grants breakthrough designations for drug candidates that show early clinical promise, compared to approved therapies, for diseases with few or no treatments. Among other benefits, breakthrough status gives companies access to accelerated approvals.

Martin Seidel, who until recently was director of GNF, said FDA approval for Zykadia is a good morale-booster for researchers in San Diego. According to Seidel, after more than a decade of research and development for therapeutic targets and novel compounds, it’s gratifying to see a new drug make its way to patients, especially since so many projects fail before they make it to the FDA finish line.

“The approval is fantastic because that’s the ultimate validation,” Dr Seidel said. “What was really exciting for the past year or two was when we were having clinicians come to GNF and talk to us about the impact on patients and showing us that their scans were clear. We all do this for the patients and because we love what we do.”

GNF is part of the Novartis Institutes for Biomedical Research (NIBR), the research and early development arm of Novartis. NIBR includes more than 6,000 scientists working at eight campuses in the U.S., Europe and Asia.

After a decade with GNF, Dr. Seidel moved to Cambridge, Massachusetts, a few months before Zykadia’s approval, to serve as global head of strategic alliances for NIBR. He returns to San Diego on occasion to visit GNF and speak with potential collaborators.

Novartis created GNF around the time the first human genome

16

Biocom LifeLines Summer 2014

was sequenced to take advantage of genomic findings from that massive project. Novartis’s kinase inhibitor Gleevec (imatinib mesylate) for leukemia and gastrointestinal stromal tumors received its first approvals around that time.

Zykadia was discovered in 2003, around the time Dr Seidel joined the San Diego research center, by scientists looking for a compound to treat anaplastic large cell lymphoma, a rare pediatric cancer. Eventually, ALK was implicated in lung and other types of cancer. Research is ongoing to support Zykadia’s approval for earlier lung cancer treatment.

GNF researchers have helped develop about a dozen compounds in Novartis’s clinical pipeline, including many seven drug candidates discovered in San Diego. Some of the compounds include: LDE225 for basal cell carcinoma; LGX818 for melanoma; the stem cell therapy HSC835 for hematological malignancies; BAF312 for multiple sclerosis; and the malaria therapy KAE609.

“We’ve now had some of the clinicians with some of the other compounds come through the GNF campus. In many cases, these compounds are treating desperate diseases and it literally brings a tear to the eye of people on the campus because the clinicians talk about how grateful the patients are,” Dr. Seidel said.

Scientists at GNF and other NIBR research facilities work on projects in oncology and metabolic, autoimmune and infectious diseases. They frequently collaborate across disease areas based on wherever the science leads them.

The San Diego research center collaborates with local academic institutions, including the Salk Institute, The Scripps Research Institute and the University of California, San Diego. Novartis researchers are matched with outside experts who gain access to research and early drug development capabilities, such as highthroughput screening, that generally are not available to academic scientists.

GNF also partners with companies, but usually around drug discovery platform technologies rather than drug targets.

“Coming to Cambridge, my role is putting together more of those collaborations,” Dr Seidel said. “We collaborate across the waterfront – academic collaborations for basic science, biotech companies for screening or antibody technology – all the way to

Guest

licensing and partnering deals, and venture capital investment.”

Novartis recently calculated its economic impact in San Diego in anticipation of a visit from U.S. congressmen Juan Vargas and Scott Peters. GNF employs about 600 people in San Diego, which translates into $95 million per year in San Diego and $135 million throughout California in payroll and other spending.

That doesn’t count the economic impact of Zykadia, GNF’s first FDA victory. As Novartis reinvests revenue from the drug’s sales, some of those dollars will come back to San Diego to fund the company’s next Gleevec or Zykadia.

Mandy Jackson writes about small and midsized biotech companies for the biopharma news website Scrip Intelligence.

Make Your Mark

in

BiotechnologY

Professional Science Master’s The Professional Science Master’s in Biotechnology is the premier degree in San Diego. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at http://www.csusm.edu/el/psmlifelines

HURRY! Fall 2014 Start

APPLY TODAY

Membership

By Kira Jenkins, Director of Membership, Biocom

BiocomConcierge.org – Time-Saving Business Solutions After years of working with our members, there’s one thing I can say for sure – they rely on Biocom as an important resource.

We field calls each day from members who are looking for another company who can provide the services that fit their business needs. We realize that every company requires help on their path to success and finding service providers they can count on can be time-consuming and difficult. So we are proud to announce our new Biocom Concierge website.

This website offers a user-friendly and searchable interface that provides recommendations on trusted service providers in the following sectors: •Financial: Whether your financial needs are raising capital or planning for your employees’ retirements, let us find you the most effective solutions.

•Lab: Your research objectives are as unique as an individual’s DNA. Find the vendors with the specialized experience to help you take your product from bench to bedside.

•Legal: You made a breakthrough discovery…now what? Protect your ideas and your company’s future with one of the most respected legal firms in our community.

•Operations: We are here to efficiently assist you in organizing your business and operational affairs.

•Professional Services: Find the essential services your business needs to thrive, while creating and preserving an inspired, dynamic and productive workforce.

With a comprehensive collection of the essentials to run a business, this service ensures that all bases are covered anytime and anywhere. Don’t risk your company’s specialized business needs by entrusting an unknown company found in a quick online search. Instead, use a Biocom member company who services and supports the life science industry here in Southern California.

Don’t spend a minute longer searching for the best service providers in Southern California. Let us do the work for you, visit www.BiocomConcierge.org.

Kira Jenkins is the Director of Membership for Biocom and also formed and spearheads Biocom’s Digital Health and CRO committees.

ALWAYS HELPFUL. ALWAYS RELIABLE. The Biocom Concierge helps connect your needs with the services of a trusted fellow Biocom member. How may we be of service?

www.biocomconcierge.org

18

Biocom LifeLines Summer 2014

EVENTS

By Shaye Exner, Senior Director of Conferences & Corporate Sponsorships

Providing Tangible Value Through Sponsorships Here is my elevator pitch: “With more than 75 educational and networking events each year, including four conferences, Biocom offers companies unparalleled sponsorship opportunities to reach a targeted audience.

Event sponsorship is an ideal way to raise your profile with Biocom members, as well as the life science industry as a whole.

Sponsorships offer direct access to the potential clients you want.

We work with all of our sponsors to ensure their marketing goals are being met, while promoting their support for the industry.

Sponsorship benefits include speaking opportunities, website visibility, brand recognition, electronic and print advertising and many others. Biocom looks forward to creating a custom benefit package designed to fit each company’s marketing strategy. Get involved today!”

Are you sold? Probably not, otherwise my job would be way too easy. I spend my days talking to companies who see Biocom as a resource. They acknowledge our reach, our value to the industry and our access to their clients, as well as potential clients. That’s the easy sell.

However, there’s also the financial investment needed to gain the highest exposure levels and the time commitment from sponsors who want to provide programming content to highlight their expertise. These are harder conversations.

I know I am selling a good product. I know that once a sponsor makes the decision to support one of our events, conferences or initiatives, they will receive tremendous ROI. I know these things because every year I have the same sponsors returning and becoming true partners. But don’t take my word for it (I am obviously just a paid sponsorship wonk), listen to those who have seen the value of their investment. Then call me.

Ideal Opportunity to Advance our Partnership Tracy Murphy, Senior Director, Leasing & Development, BioMed Realty Trust Being the co-lead sponsor of the 2013 Annual Celebration of Life Dinner was a long-awaited and ideal opportunity for BioMed Realty to advance our partnership with Biocom. We share a mission of supporting and accelerating the success of the San Diego life science community, which has contributed so much to quality of life and inspires us day after day.

20

Biocom LifeLines Summer 2014

The 2013 event was an unqualified success, attracting the best and brightest executives and leaders from throughout our biotechnology cluster, along with state and local government leaders – including the Governor of California. This exemplifies Biocom’s commitment to bringing the entire industry together to benefit the community we serve.

As the leading provider of real estate solutions to the San Diego life science community, BioMed Realty has a proven track record of bringing unmatched expertise to the full range of real estate services for our tenant partners. For those of us with the privilege of supporting the transformational research and groundbreaking science in laboratories and research facilities throughout the city, attending the annual dinner helps us salute the innovation, creativity and successes that are enhancing the quality of life, as well as the sustained leadership of the industry, and generating economic growth and opportunity in San Diego.

By being a lead sponsor of the event, BioMed Realty continued to show our commitment to San Diego’s life science community.

We received significant exposure to our company through the event program, visuals displayed in the room throughout the evening including our logo captured in event photos and, most importantly, from the honor of introducing the keynote speaker for the evening, the incomparable and inspirational Jill Bolte Taylor.

For these reasons, and many more, we are pleased to again be the co-lead sponsor of the Biocom Annual Dinner and look forward to an even more successful event in 2014.

Save the Date for the 2014 Biocom Annual Dinner, Thursday November 20.

Opportunity furthers our mutual focus on advancing the quality of leadership in the San Diego life sciences community Leland Sandler, Executive Advisor, The Sandler Group The Sandler Group has had the opportunity to sponsor two CEO dinners with Biocom in the past six months. This opportunity to work with Biocom furthers our mutual focus on advancing the quality of leadership in the San Diego life sciences community. Both dinners have been unqualified successes, largely due to the exceptional moderators: Carol Gallagher, former CEO of Calistoga Pharmaceuticals, and

currently a venture partner at Frazier Healthcare; and Kleanthis Xanthopoulos, CEO of Regulus Therapeutics. The goal of these dinners was to discuss key issues faced by CEOs in their ever-changing environment.

The CEO Dinner topic was initially focused on lessons learned from different business models: partnership, acquisition or IPO. We discussed what to do and when to do it, as well as the importance of having the right team, the right organization and the right board members.

But the conversation went on to growing leadership, building teams, optimizing execution, creating sustaining cultures, effectively dealing with boards, fostering innovation and building the reputation and status of San Diego in the worldwide life sciences community.

These opportunities for CEOs to get together to discuss real issues exemplify Biocom’s commitment to its members and the leaders of these companies.

The Sandler Group works with life science CEOs and senior executives to change their thinking, behaviors and attitudes to help them achieve their fullest potential. We design organizational, senior team and senior executive solutions that are unique to each client, yet focused on a common goal. We want to create and foster a culture and mindset of sustainable excellence that enables senior leadership teams to drive effective and efficient execution throughout their organizations.

The Sandler Group is privileged to sponsor our next CEO dinner in November 2014. Our goal is to host a series of these dinners for CEOs, and other senior executives.

Defining Gas and Cryogenic Solutions for the Life Sciences Praxair – the largest industrial, medical, and specialty gases supplier in North America – offers a comprehensive portfolio of gas products with the purity, compliance, and certification needed for your research or manufacturing application.

• Supply at all scales • Piping and distribution systems • ProStar gas equipment • Convenient e-commerce options • Expert customer support • Productivity and safety focus TM

Shaye Exner is the Senior Director of Conferences and Corporate Sponsorships, she also oversees the programming for all Biocom Events.

Contact: Tom_Cole@praxair.com 619-512-7973

Let’s be Social. linkedin.com/company/biocom @biocomca

facebook.com/biocom flickr.com/biocom

don’t be shy... say hello

Mayer Hoffman McCann P.C .

A Proud Sponsor of BIOCOM A national CPA firm Serving life science companies locally for over 30 years A national Life

Mass Spec L A B

Science Practice headquarted in San Diego

Assisting companies succeed in all stages of growth - from startup to going David Diamond

public or being acquired davidd@cbiz.com

858.795.2014 www.mhmcpa.com

@cbzmhm_sd

Mass Spec L A B Delivering ppm-level accurate

mass determinations using state-of-the-art LC-ESI-QTof & APGC-QTof instruments

Email us: info@massspeclab.com or call (949) 872-2724

Science Festival

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

Festival Week a Big Success And we’re just getting started

With more than 24,000 attendees at EXPO day, and more than 60 percent attendance growth during our Festival Week events and activities, the San Diego Festival of Science & Engineering proudly kicked off 2014 with a bang.

If you were at EXPO day, a loud bang is just one of the many sensory experiences you would have encountered. From General Atomics’ thrilling explosions, to the Reuben H. Fleet making “elephant toothpaste,” to visiting with our friendly creatures at EcoVivarium, there was something for science, technology, engineering, and math (STEM) enthusiasts of all ages.

The Festival of Science & Engineering is an integral, communitywide event in San Diego and its success relies on direct community support. Thanks so much to all of our 2014 sponsors who made this week possible.

Presenting Sponsor: Illumina Gold Sponsors: ABC 10, Azteca San Diego 15, Biocom, Biocom Institute, Biocom Purchasing Group, Jammin Z’ 90, Magic 92.5, Qualcomm Foundation, San Diego Padres, UT San Diego, ViaSat Inc. Silver Sponsors: Cox Media, KYXY 96.5, Thermo Fisher, Reuben H. Fleet Science Center, San Diego County Office of Education, Time Warner Cable, UC San Diego, VWR Copper Sponsors: California Endowment, Cubic, Cymer, Hewlett Packard, Office Depot, Mother’s Cookies, Sapphire Energy Inc., Scatena Daniels Communications, Think Blue San Diego, UTC Aerospace Systems - Aerostructures, Vertex Krypton Sponsors: American Elements, Bank of America, Celgene, EMD Milipore, Pfizer Inc., Sequenom Titanium Sponsors: Animal Jam, Ardea Biosciences, BP Biofuels, Capistrano Connections Academy, D&K Engineering, General Atomics, Kaiser Permanente, LEGOLAND California and SEA LIFE Aquarium, San Diego Whale Watch, San Diego Center for Systems Biology, San Diego Chapter of National Defense Industrial Association, SeaWorld San Diego, Novartis, Nuvasive, Inc., Point

Loma Nazarene University, Raytheon Educational Sponsors: Ferring Pharmaceuticals, Kimmich Foundation, San Diego Financial Literacy Center, UTC Aerospace Systems - Aerostructures, Vertex In addition to all our amazing sponsors, we had more than 150 businesses and organizations take part during festival week events and as exhibitors during the EXPO. Their support helped us inspire future generations of STEM innovators. Without the support of the San Diego community – businesses, schools and families – our mission wouldn’t be possible. So THANK YOU San Diego – you are amazing.

Summer STEM Challenge The San Diego Festival of Science & Engineering is excited to announce our latest initiative to engage students year-round in science, technology, engineering, and math: the Summer STEM Challenge. To help our future innovators to stay excited about learning throughout the summer, we are providing activities that will excite their minds and provide a platform for collaborative teaching and learning by sharing these projects with friends and family.

The Festival will post daily “do it yourself” STEM experiments on our Facebook page. The projects will range in level as well as STEM discipline. Children and parents will have the chance to submit a summary of their DIY projects, along with pictures, at the end of June, July and August. Participants earn the opportunity to win a STEM activity basket with fun summer prizes, including tickets to local museums and attractions. Elementary, middle and high school winners will be chosen.

For more information on the Summer STEM Challenge, and other STEM education opportunities, log onto our website at www. sdsciencefestival.com.

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

Biocom LifeLines Summer 2014

23

Biocom Institute

By Liisa Bozinovic, Executive Director, Biocom Institute

Veterans in Life Sciences According to the U.S. Bureau of Labor Statistics, the unemployment rate for veterans 18 and older in California is 7.9 percent, compared to 8.7 percent for nonveterans. Many employers recognize that veteran employees have exceptional leadership skills and can work both in teams and independently. Veterans maintain strong respect for procedures and accountability and bring other attributes that make them great employees. Employers also report that most veterans on-board more quickly during their first year and advance faster than non-veterans.

While the unemployment numbers are down, studies show that people are leaving military service at rates unprecedented since the end of World War II. This trend is expected to continue over the next five years. The Military Transition Support Project estimated that 15,000 sailors and Marines stationed in San Diego leave the service annually and 50 percent of these veterans and their families will stay in San Diego. Since San Diego is home to the third highest veteran population in the United States, our businesses are well-positioned to take advantage of this great national asset.

In addition to having the desirable skills they have learned and practiced during their time on active duty, a Student Veterans of America (SVA) report shows that 51.7 percent of veterans have received a postsecondary degree or certificate. Their completion rates are similar to traditional college students and better than other nontraditional students. But regardless of the type of training they received and whether or not they have a degree, veterans still have to navigate how to transfer their military skills into civilian ones, and this can be a daunting task.

Biocom Institute is poised to help veterans transition from military to civilian careers in Southern California and has formed a Veterans Initiative Committee, with members to focus on veterans’ specific workforce development needs. The committee brings a wide cross-section of veteran and nonveteran members: CEOs, educators, legal, IT human resources and business development professionals. One thing they all have in common is a passion for helping veterans acquire the necessary skills and confidence they need to successfully transition to a civilian career in the life science industry.

The committee’s first initiative is a four-month pilot mentorship program, during which veteran job seekers will be paired with veteran industry members. In addition to direct mentoring, the unemployed veterans in the program will receive training

24

Biocom LifeLines Summer 2014

in networking, resume writing and interviewing. They will also have networking opportunities at three industry conferences: Biotechnology Industry Organization’s annual international convention in San Diego this June, Biocom’s DeviceFest and Expo in August and Biocom’s HR conference in September. They will also participate in mock interviews with top HR professionals.

Most importantly, they will have a veteran mentor whom they can call on for advice, moral support and personal connections into the industry.

Through an informal survey of our life science member companies, we are finding that, while many of them understand the benefits of hiring veterans, they do not have a targeted method to accomplish this. In addition, they have trouble deciphering a veteran’s resume and understanding how their skills might apply to the open positions within their company. Some larger companies, such as CareFusion with their Veteran Integration Program, have robust diversity programs with veteran components.

The committee’s aim is to facilitate the hiring of veterans with our smaller member companies by sharing best practices from the CareFusions in our membership.

There are many ways for your company to get involved in this initiative, such as joining the committee, providing internship opportunities or encouraging your employees to be mentors.

Please let us hear from you by taking 10 to 15 minutes to fill out our survey at www.surveymonkey.com/s/lifescienceveterans or by contacting us directly at areynolds@biocom.org.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR initiative.

Biocom LifeLines Summer 2014

25

Purchasing Group

By Rick Fultz, Managing Director, Biocom Purchasing Group

Power in Numbers

A case study of the Biocom RFP process Since we were first formed in 1997, the Biocom Purchasing Group has been evolving the process through which we select bestin-class suppliers. Our RFP process is how we vet and exclusively endorse our Platinum Suppliers. It is the principal element of our business model and relies heavily on the expertise and time commitments of key individuals from our member companies. The unique opportunity to connect with numerous experts from our membership has generated substantial growth, both in quality and quantity, of our committee participation over the past few years.

It is this growth that fuels our portfolio’s constant improvement.

RFP Overview The RFP process starts with the selective recruitment of an ad hoc committee of talented and experienced individuals from member companies of all sizes across all industries. Over the course of the RFP, the committee develops a list of eligible candidates and an in-depth questionnaire, requests product or service trials, analyzes data, conducts site visits and reviews results from routine member surveys. Several rounds of questions and price negotiations follow and the process narrows down to finalists, and then eventually a winner. The process can last anywhere from three to six months, depending on how much due diligence the committee feels is necessary before a decision can be made.

Case Study: Garment and Cleanroom RFP In January, 22 procurement executives from Biocom’s largest and most influential member companies came together to form a highly qualified committee in search of a best-in-class provider for both reusable garment and cleanroom solutions. Given the magnitude of the represented companies and the expertise of the individuals, this was by far the most powerful committee we have ever put together. The RFP panel represented over $7 million in garment spend and another $2 million in cleanroom spend, and had a combined 300 years procurement experience.

The RFP was extended to eight companies servicing Southern California. Candidates were evaluated independently for both garments and cleanroom capabilities. During this process, the committee investigated discount structures, service level agreements, associated terms and fees and garment quality as well as facility proximity, quality and functionality. Two finalists were eventually selected to present in March.

For the first time in Biocom’s history, $1.3 million was committed to the RFP process by committee participants and other pivotal

26

Biocom LifeLines Summer 2014

Biocom member companies, as well as buy-in from BayBio in San Francisco. Leveraging BayBio’s 450 additional members and this unprecedented level of committed spend provided the impetus that led to some dramatic concessions, special terms and conditions and favorable fee structures. There is great power in numbers; whether in the form of a strong committee, a collaboration with BayBio, or in member-committed spend. The process worked and our members get to reap the benefits.

We are proud to announce that UniFirst, a leading supplier of workwear programs for businesses of all sizes since 1936, was the clear winner of the garment and cleanroom endorsement.

Their leadership team was engaging and dedicated throughout the entire RFP process and was the driving force behind their success. Their ISO-certified Milpitas facility is equipped with an advanced proprietary microchip-scanning technology, highly efficient production processes, flexible customization to meet member needs of all sizes, knowledgeable staff and an exceptional company culture. UniFirst demonstrated the perfect mix of life science expertise, commitment to quality, global presence and technological innovation. Their offerings to Biocom members include unprecedented levels of negotiated pricing for uniforms and facility services, coupled with top quality products, waived initiation fees and dedicated customer service.

When our members align, there is great power in numbers. Our process is predicated on this, and we would love for you to be a part of our evolution. For more information on the RFP process, or the UniFirst contract, please feel free to contact us at PGSupport@ biocom.org.

Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

PREMIUM MEMBER SPOTLIGHTS PREMIUM MEMBERS AbbVie Ajinomoto Althea Alexandria Real Estate Equities Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Biospace BP Biofuels Cadence Pharmaceuticals California Manufacturing Technology Consulting Canale Communications Celgene City National Bank* COI Pharmaceuticals Conatus Pharmaceuticals Cooley County of San Bernardino Economic Development Agency Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic Janssen Research & Development Jones Day KPBS Latham & Watkins Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Patheon Pfizer Praxair PwC Thermo Fisher Scientific VWR International Wilson Sonsini Goodrich & Rosati * New Members from January 2014 to May 2014

28

Biocom LifeLines Summer 2014

www.altheatech.com Name: Kristin DeFife Job title: Director, Biologics Manufacturing Favorite movie: Shawshank Redemption Favorite book: The Girl with the Dragon Tattoo Trilogy Favorite quote: “It’s all in the execution.” Henry VIII Favorite TV show: Damages Favorite restaurant or meal: Steak, baked potato, carrots Favorite city: Napa Valley, as of my 1st visit in April Favorite actor/actress: Kevin Spacey Favorite thing to do on the weekends: Relax with friends What CD can we find in your car: Avenue Q Favorite hobby: Kayaking Favorite website: Thankfully, none Favorite spot in Southern California: My house First job: Cashier at a 99 cent store Favorite part of your job: Successes with my team If you could have another career, what would it be: Music industry A&R Why did you start working in your industry: My high school AP Biology teacher just made cells so darn interesting

www.conatuspharma.com Name: Karen Valentino Ph.D. Job title: Vice President, Program Management Favorite movie: The Philadelphia Story, Bull Durham Favorite book: Too many to pick just one or two or three Favorite quote: ‘This is a very simple game. You throw the ball, you catch the ball, you hit the ball. Sometimes you win, sometimes you lose, sometimes it rains.” Bull Durham Favorite TV show: The Good Wife, Parks and Rec, Veep Favorite restaurant or meal: The Wine Vault and Bistro (Mission Hills) Favorite city: Rome Favorite actor/actress: Cary Grant, Katharine Hepburn Favorite thing to do on the weekends: Hang out with the dogs, watch a Padres game What CD can we find in your car: anything by Highland Way Favorite hobby: yoga (not just a hobby!)

Favorite website: Facebook Favorite spot in Southern California: Coronado dog beach First job: Food service Favorite part of your job: Working with my fabulous colleagues!

If you could have another career, what would it be: Historian Why did you start working in your industry:The opportunity to apply basic research to benefitting human health.

PREMIUM MEMBER SPOTLIGHTS www.mintz.com

www.praxair.com

Name: Fred Hernandez Job title: Member, Patent Attorney

Name: Tom Cole Job title: Territory Manager, BioPharma

Favorite movie: The Empire Strikes Back Favorite book: Lord of the Rings Favorite quote: Deserves got nothing to do with it.

Favorite TV show: Game of Thrones Favorite restaurant or meal: Sushi Favorite city: Florence Favorite actor/actress: Clint Eastwood Favorite thing to do on the weekends: Spend time with family What CD can we find in your car: Codes and Keys Favorite hobby: Mountain biking Favorite website: Raiders.com Favorite spot in Southern California: San Diego First job: Hamburger cook at McDonalds Favorite part of your job: Working with smart people If you could have another career, what would it be: Zookeeper Why did you start working in your industry: To be involved in a technology related and challenging career

Favorite movie: Blade Runner Favorite book: Brave New World Favorite quote: “Live as if you were to die tomorrow.

Learn as if you were to live forever” - Mahatma Gandhi Favorite TV show: Breaking Bad Favorite restaurant or meal: Coyote Cafe, Old Town Favorite city: Tokyo Favorite actor/actress: Jack Nicholson Favorite thing to do on the weekends: Local discovery road trip with the family What CD can we find in your car: Full Moon Fever - Tom Petty Favorite hobby: Travel Favorite website: WonderHowTo Favorite spot in Southern California: La Jolla Cove First job: Attendant at a Sunoco gasoline station Favorite part of your job: Meeting and talking with people about what they do If you could have another career, what would it be: Someone that creates that next great life changer Why did you start working in your industry: I began studying biology and sociology but gained interest in business. I managed or owned electronic and equipment manufacturing or services companies. I became a sales rep for a semiconductor services company that required knowledge in the specialty gases, and saw wider applications in the gases and cryogenics side.

www.vwr.com

Name: Melanie McRae Job title: Director, Regional Sales Favorite movie: Steel Magnolias..Nothing like a good cry and laugh at the same time.

Favorite book: The Giving Tree....look for it on your child’s bookcase.

Favorite quote: “Great minds discuss ideas; Average minds discuss events; Small minds discuss people”--Eleanor Roosevelt Favorite TV show: Shaq All-star Comedy Jam Favorite restaurant or meal: Collard Greens made with ham hocks!

Favorite city: San Diego....(I have a born and raised bias!)

Favorite actor/actress: Ray Liotta

Favorite thing to do on the weekends: Going to Hilltop Park with my 4 year old.

What CD can we find in your car: Best of Duran Duran..what can I say? I am an 80’s fan!

Favorite hobby: Cooking new recipes.

Favorite website: www.TED.com Favorite spot in Southern California: A bench positioned in front of the monkeys at San Diego Zoo First job: Neighborhood babysitter....knew I was born to be a mom way back then!

Favorite part of your job: I learn and share something new each day.

If you could have another career, what would it be: An author of fiction novels.

Why did you start working in your industry: Everyday I have a chance to enable others, through science, to make a difference and improve our lives. My mom is a breast cancer survivor and I know, first hand, that new scientific developments will play a large part in the quality of my life and my family’s life forever.

Biocom LifeLines Summer 2014

29

69,808 square feet

10,335 square feet

We are pleased to announce that AltheaDx and Arcturus Therapeutics have each chosen to relocate their corporate headquarters to the Torrey Ridge Science Center in the coming months!

Additional class A laboratory space

AVAILABLE 10,000 to 250,000 square feet

For more information, please contact:

Rich Danesi Lic. 01869864 +1 858 546 4652

richard.danesi@cbre.com

Ryan Egli Lic. 01445615 +1 858 546 4648 ryan.egli@cbre.com

Board of Directors BOARD OFFICERS AND EXECUTIVE COMMITTEE: CHAIR: Magda Marquet, Ph.D., Ajinomoto Althea* VICE CHAIR: Carin Canale-Theakston, Canale Communications* CHAIR ELECT: Theodore Schroeder VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* VICE PRESIDENT – INDUSTRY: Daniel Burgess PRESIDENT & CEO: Joe Panetta, Biocom* Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Michael Boyd, AbbVie Michael Brown, Stradling Yocca Carlson & Rauth Terrance J. Bruggeman, BioTork, LLC Timothy Caulfield John M. Dunn Geoffrey S. Eich, Amgen Stephen Ferruolo, J.D., Ph.D., USD School of Law* M. Wainwright Fishburn, Jr., Cooley LLP* Don Fitzgerald, Genentech Jack Florio, Brinson Patrick Securities Gregory Fond, Sanofi Global R&D Gregory Frost, Intrexon Corp.

Alan Gold, BioMed Realty Trust Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Terry Gregg, Dexcom Jason Hannon, NuVasive Richard Heyman, Ph.D., Seragon Pharmaceuticals Jim Hinrichs, CareFusion Elliot Hirshman, Ph.D., San Diego State University Matthew Hudes, Deloitte LLP Guy J. Iannuzzi, Mentus David Kabakoff, Ph.D., Sofinnova Ventures Steve Kaldor, Ph.D., Quanticel Michael Kamdar, Cellana, Inc. Katherine Kantardjieff, Ph.D., California State University San Marcos Paul Laikind, Ph.D., ViaCyte Kevin Larkin, TherOx Jacob Levin, Ph.D., UC Irvine James Levine

Jack Lief, Arena Pharmaceuticals, Inc.* Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* William Molloie, PwC Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.* Brian O’Callaghan Kenneth Polin, Jones Day Trindl Reeves, Barney & Barney LLC* Gregory Reyes, M.D., Ph.D., Celgene Dan Ryan, Alexandria Real Estate Equities Camille Saltman, MD Revolution James Schaeffer, Ph.D., Merck Research Laboratories* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek* Martin Seidel, Ph.D., Genomics Institute of the Novartis Research Foundation Bhasker Shetty, Ph.D., Pfizer La Jolla Larry Stambaugh* Mark Stevenson, Thermo Fisher Scientific* David Webb, Ph.D.* Scott N. Wolfe, Latham & Watkins Randall E. Woods, Sophiris Bio* LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects* David Hale, Hale BioPharma Ventures* Tina Nova, Ph.D. Biocom Board Members-Ex-Officio: Sandra Brown, Ph.D., UCSD Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Scott Lippman, MD, Moores Cancer Center, UCSD Greg McKee, CONNECT Peter Preuss, The Preuss Foundation Jerry Sanders, San Diego Regional Chamber of Commerce *Executive Committee Member

Committee leadership Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Laboratories, Inc. Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield FDA Committee Magda Marquet, Ph.D., Ajinomoto Althea Michele Yelmene, Pharmalink Consulting

Intellectual Property and Patent Law Committee Margaret Dunbar, Sanford-Burnham Medical Research Institute Daniel Hart, Knobbe Martens Olson & Bear LLP Legislative Committee Richard Ledford April Grant, Sunovion Pharmaceuticals Medical Device Committee Noel Gillespie, Procopio, Cory, Hargreaves& Savitch Joleen Schultz, Rady School of Management, UCSD Digital Health Committee Camille Saltman, MD Revolution

Public Policy Oversight Committee* Larry Stambaugh Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Scholarship Committee Bente Hansen, BenteHansen and Associates Biocom Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.

Biocom LifeLines Summer 2014

31

Biocom MEMBERSHIP PREMIUM

California Manufacturing Technology Consulting Canale Communications Celgene City National Bank* COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP County of San Bernardino Economic Development Agency

Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic

Janssen Research & Development Jones Day KPBS Latham & Watkins Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive

Patheon Pfizer Praxair PwC Thermo Fisher Scientific VWR International Wilson Sonsini Goodrich & Rosati

Biotechnology

BioTork BioWa Boehringer-Ingelheim Curtana Pharmaceuticals CalciMedica CannaVest Corporation CARBOGEN AMCIS Cebix Cell Applications Celladon Cellana Cell Signaling Technology Center for Aquaculture Technologies Cibus Coda Therapeutics Conju-Probe Contract Biotics Crinetics Pharmaceuticals* CURx Pharmaceuticals Custopharm Cypher Genomics* Dart Neuroscience Denovo Biomarkers DSM Food Specialties eFFECTOR Therapeutics Electronic BioSciences eMolecules Epeius Biotechnologies Equitech Bio Fabrus Fate Therapeutics Formex Genelux Corporation Genentech Genlantis Genoa Pharmaceuticals Genomatica Genovo Corporation GenSignia Life Sciences GlaxoSmithKline Guangdong Consun Pharmaceutical Company GWR Instruments

Halozyme Therapeutics Harbor Therapeutics Histogen Human Longevity* Huya Bioscience International IDEXX BioResearch* Illumina Imprimis Pharmaceuticals* Inception Sciences Inhibrx InnoPep Innovative Cell Technologies Inovio Pharmaceuticals Integrated DNA Technologies Intercept Pharmaceuticals International Stem Cell Intrepid Therapeutics Intrexon Corporation* Intrinsic LifeSciences Invetech InvivoGen IRBCo. ISIS Pharmaceuticals Jaleva Pharmaceuticals J-Oil Mills Kalyra Pharmaceuticals Koltan Pharmaceuticals* Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Lithera Lpath Lumena Pharmaceuticals MabVax Therapeutics Malama Composites* Mast Therapeutics MEI Pharma Meritage Pharma Miltenyi Biotech* Mirati Therapeutics* Monsanto Nautilus Environmental

NaZura BioHealth NeuroGenetic Pharmaceuticals Nitto Denko Technical Novartis Pharmaceuticals Novo Nordisk Nucelis Ocera Therapeutics Optimum Therapeutics Orexigen Therapeutics OrPro Therapeutics* Otonomy Pacira Pharmaceuticals Panmira Pharmaceuticals Pathway Genomics Pfenex PharmAkea Polaris Group Polynoma PolyPeptide Group Predictive Biology Preventice PrimaPharm PrimeGen Biotech Prognosys Biosciences ProSci QED Bioscience Quanticel Pharmaceuticals Receptos Regulus Therapeutics REKA Health Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies Ridgeline Engineering Roche Applied Science Rohto Pharmaceutical* RQX Pharmaceuticals RuiYi Samumed Sanguine BioSciences Sanofi Scripps Laboratories Senju USA

Senomyx SentĂŠ Seragon Pharmaceuticals SG Biofuels Shin Poong Pharmaceutical Company Sirenas Marine Discovery Solstice Biologics SoluLink Sophiris Bio Sorrento Therapeutics SOVA Pharmaceuticals Stemedica Cell Technologies Sunovion Pharmaceuticals Synthetic Genomics Takeda Pharmaceuticals U.S.A. Tanabe Research Laboratories Tenova Pharmaceuticals Thesan Pharmaceuticals Tocagen Tonbo Biosciences TP Therapeutics* Tracon Pharmaceuticals Tragara Pharmaceuticals Triphase Accelerator Trius Therapeutics UCB US Specialty Labs Vala Sciences Vantari Genetics Vaxiion Therapeutics Verdezyne Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Viking Therapeutics* Vital Therapies Wellspring Biosciences Wildcat Discovery Technologies Zensun USA Zogenix

CRO/CMO

Behavioral Pharma Bend Research BioAtla Bioserv Corporation CalChem Synthesis Cassia* Cato Research Charles River Laboratories ChemDiv Concortis Biosystems Cytelligen Davos Chemical DD Studio* Denovo Biomarkers* Epistem

eStudySite Exon BioSystems Explora BioLabs GENEWIZ GRAM Laboratories Hamari Chemical San Diego Research Center Huntingdon Life Sciences Integrium Clinical Research Interplex Sunbelt* inVentive Health Clinical* IriSys JadeBio LCMS Solutions* MicroConstants

Molecular Response MPI Research Neuroservice Neuro-Sys* OOxesis Biotech PacificGMP PharPoint Research Pharmatek Laboratories Profil Institute For Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox Reveal Biosciences Rho

Robarts Clinical Trials SAFC Pharma SeqWright Genomic Services Sherpa Clinical Packaging SynteractHCR Therapeutics, Inc. Tioga Research Toxikon Triligent International Ultimate Labs Verum.us Virapur Wax-It Histology Services Zensun USA* Zyagen

AbbVie Ajinomoto Althea Alexandria Real Estate Equities Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Biospace BP Biofuels Cadence Pharmaceuticals

Abgent Abide Therapeutics Abwiz Bio ACADIA Pharmaceuticals ActivX Biosciences Advanced BioMatrix Advanced Targeting Systems Aerie Pharmaceuticals Afraxis Aires Pharmaceuticals Allylix AM Chemicals AMBRX Ambryx Biotechnology* Amgen Amicrobe Amplyx Pharmaceuticals Amylin Pharmaceuticals AnaptysBio AndroScience Ansun Biopharma* Apricus Biosciences Arcturus Therapeutics Ardea Biosciences Arrayomics Astellas Pharma aTyr Pharma Auspex Pharmaceuticals Avantgen Avelas Avidity NanoMedicines* Aviva Biosciences Bachem Americas BASF BioLegend Biomatrica Biomyx BioNano Genomics Bionomics Bio Options BioSpyder Technologies

Abbiotec Absorption Systems Accelagen Accugent Laboratories Acurian Advantar Laboratories Agility Clinical Alliance Protein Laboratories Ambit Biosciences American Peptide Company AMRI Annova Chem ARIANNE Atheln*

32

Biocom LifeLines Summer 2014

Medic al Device & Diagnostic

Cell Idx CeloNova BioSciences Celula Cliniqa Corporation ClinMet Compellon CRISI Medical Systems Critical Diagnostics CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom Diagnostic Consulting Network Ellipse Technologies Emerge Diagnostics* Enigma Diagnostics Entra Health Systems Epic Sciences

Epitope Diagnostics Fallbrook Engineering FemCap Fortimedix USA Freedom Meditech GenWay Biotech Glaukos Corporation Glysens Hitachi Chemical Research Center Ichor Medical Systems Ignyta ImpediMed ImThera Medical Inceptus Medical INOVA Diagnostics Interventional Spine InVision Biomedical Group Invivoscribe Technologies Ionian Technologies

Ivantis Ivera Medical KFx Medical Liferiver MARDX Diagnostics MD Revolution Micell Technologies Millennium Laboratories Nano Imaging Services OncoSec Medical Organovo Prometheus Laboratories Qualigen Quidel Quinn Medical* ReShape Medical REVA Medical Reverse Medical ReVision Optics

Ridge Diagnostics Roka Bioscience Sequenom Shire Sienna Labs Sirigen Sonendo SpectraScience Suneva Medical Tandem Diabetes Targeson Tensys Medical TherOx Tristan Technologies Trovagene Uptake Medical Yulex

Key Provider

Blue Sky Broadcast Bootstrap Incubation Brinson Patrick Securities Caliber Associates California Commercial Security Canteen Vending Services CBRE China Business Partners Chubb Group of Insurance Companies Clinigen Healthcare Controlled Contamination Services Cox Business CSCI* Cymer Domain Associates EBD Group Elsevier Enterey EquipNet Euretos Exp U.S. Services* Ferguson Pape Baldwin Architects Fish & Richardson Fisher & Phillips Forward Ventures Fragomen, Del Rey, Bernsen & Loewy*

French Biobeach Frequentz Gable PR* Gamxing* Gensler Grande Colonial Grant Thornton HCP Life Science Estates H.G. Fenton Company* Hyatt Regency La Jolla at Aventine Innovative Commercial Environments Innovative Lease Services J.T. MacMillan Photography Jackson & Blanc HVAC Contractors Jones Lang LaSalle KBM Facility Solutions Kilroy Realty Knobbe, Martens, Olson & Bear Leadership Edge Legacy Partners Commercial Levementum LG Technology Center of America Managed Solution Mayer Hoffman McCann McKenna Long & Aldridge Morgan, Lewis & Bockius

Morrison & Foerster Occupational Services Office Depot OfficeMax / Workplace Interiors Ogletree, Deakins, Nash, Smoak & Stewart Outlier Solutions* Oxford Finance Pegasus Cleanroom Services Pharmalink Consulting PR Newswire Prevost Construction Procopio, Cory, Hargreaves & Savitch Project Management Advisors Prudential Cleanroom Services Relocation Coordinates Retirement DNA San Diego World Trade Center Sartorius SecureDocs Scient Federal Credit Union Sharp Business Systems Sheppard Mullin Richter & Hampton Shred San Diego Signature Analytics* Silicon Valley Bank

SLM Group Sofinnova Ventures Sonceboz Corporation Square 1 Bank S Squared Executive Search Stradling Yocca Carlson & Rauth Studley Sughrue Mion Synergy Corporate Housing* Tata America International* Technical Safety Services The Business Cleaning Company The HealthEd Group The Sandler Group Thomas, Mcnerney & Partners T-Mobile USA United Parcel Service (UPS) Urban Contracting VDP Direct Veolia Virgin America Vision33 WCCT Global*

Human BioMolecular Research Institute Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute Kaiser Permanente KOTRA - Los Angeles La Jolla Bioengineering Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center Los Angeles Biomedical Research Institute Medicon Valley Alliance* MiraCosta College Biotech Program Mt. San Jacinto College PhRMA

Point Loma Nazarene University Quebec Government Rady School Of Management, UCSD Salk Institute For Biological Studies San Diego Biomedical Research Institute* San Diego Clinical and Translational Research Institute, UCSD San Diego Community College District San Diego Employers Association San Diego Natural History Museum San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp.

San Diego Supercomputer Center (UCSD) San Diego Workforce Partnership

Sanford-Burnham Medical Research Institute Scottish Development International Scripps Health Scripps Research Institute Swedish American Chamber Of Commerce San Diego The BioIndustry Association The Lowy Medical Research Institute (LMRI) Torrey Pines Institute for Molecular Studies UC San Diego Extension UCI’s Office of Research UCSD, Department of Bioengineering UCSD, Office of Advancement UCSD School of Medicine UCSD, Technology Transfer Office

UK Trade & Investment University of San Diego

Acon Laboratories Aethlon Medical Alphatec Spine AltheaDx America Diagnostics Applied Proteomics Astute Medical BeneChill Biocept BioDx Biological Dynamics bioTheranostics Breathe Technologies Bruin Biometrics CareFusion

Airgas Barney & Barney Cushman & Wakefield Oracle Health Sciences Qualcomm San Diego Gas & Electric

Provider

2Connect Accelrys ADVI* AIS (American Internet Services) AMN Healthcare Assay Depot Austin Commercial Beckloff Associates Bente Hansen & Associates Bionest Partners Biosources BioSurplus Biotech Primer Biotech Vending BioTix

Non-Profit

American Cancer Society, Border Sierra Region American Red Cross - San Diego CA Institute for Regenerative Medicine Calibr California Baptist University, College of Engineering California State University, San Marcos City Of Murietta CONNECT Consulate Of Canada CSU,CSUPERB Program Escondido Union High School District Foundation For Personal Financial Education

Individual Antoinette Azevedo Bernard King Carol Gallagher Donna Janson* Elliot Parks Gary Friedman John Dunn* John Kavanagh Julie Ames Larry Stambaugh Peter Preuss Richard Ledford

* New Members from January 2014 to May 2014

Biocom LifeLines Summer 2014

33

4510 Executive Drive, Plaza One San Diego, CA 92121-3021 www.Biocom.org Please send a change of address or subscription request to Katelyn Doyle at kdoyle@Biocom.org.

Achieve professional success through Life Science continuing education programs.

Coming July 2014...

Through cutting-edge certificates and courses, UC San Diego Extension’s professional development programs enhance skills development in critical Life Sciences occupations.

Choose from a wide variety of classes and programs attracting both individuals and organizations alike.

This 3-day workshop, taught by faculty and practitioners, is designed to provide a deep dive into bioreactor operations for microbial fermentations.

Explore Life Sciences programs in: • • • • •

Biostatistics & Data Analytics Biotechnology Project Management Diagnostics Drug Discovery/ADMET Industrial Biotechnology (Biofuels, Fermentation)

• • • • •

Intellectual Property Life Sciences IT Medicinal Chemistry Quality Assurance and Control Regulatory Affairs

Microbial Fermentation Workshop July 30-August 1, 2014

Topics Include: • Biological Principles • Bioreactor Operations • Scale-Up of Bioreactors

• Bioprocess Monitoring • Microbe Cultivation • Design of Experiments

PLUS…Fermentor Demonstrations by DC Biolafitte.

Developed in partnership with

For your convenience, many of our certificates and courses are offered online!

For more information: (858) 534-9353 | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences